[(1R)-3-methyl-1-[(2R)-3-(2H5)phenyl-2-(pyrazin-2-ylformamido)(2H3)propanamido]butyl]boronic acid

• ChemBase编号: 162700
• 分子式: C19H25BN4O4
• 平均质量: 384.2372
• 单一同位素质量: 384.1968857
• SMILES: c1cncc(n1)C(=O)N[C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)Cc1ccccc1
• Canonical SMILES: CC(C[C@@H](B(O)O)NC(=O)[C@H](NC(=O)c1cnccn1)Cc1ccccc1)C
• InChI: InChI=1S/C19H25BN4O4/c1-13(2)10-17(20(27)28)24-18(25)15(11-14-6-4-3-5-7-14)23-19(26)16-12-21-8-9-22-16/h3-9,12-13,15,17,27-28H,10-11H2,1-2H3,(H,23,26)(H,24,25)/t15-,17+/m1/s1
• InChIKey: GXJABQQUPOEUTA-WBVHZDCISA-N

名称和登记号

名称

• IUPAC标准名: [(1R)-3-methyl-1-[(2R)-3-(^2H₅)phenyl-2-(pyrazin-2-ylformamido)(^2H₃)propanamido]butyl]boronic acid
• IUPAC传统名: (1R)-3-methyl-1-[(2R)-3-(^2H₅)phenyl-2-(pyrazin-2-ylformamido)(^2H₃)propanamido]butylboronic acid
• 别名: Velcade-D8, [(1R)-3-Methyl-1-[[(2S)-1-oxo-3-phenyl-2-[(pyrazinylcarbonyl)amino]propyl]amino]butyl]-boronic Acid-D8; Bortezomib-D8 (Major)

登记号

• PubChem SID: 162256835
• PubChem CID: 45038428

理论计算性质

• Acid pKa: 13.037311
• 质子受体: 6
• 质子供体: 4
• LogD (pH = 5.5): 1.5302998
• LogD (pH = 7.4): 1.5302991
• Log P: 1.5303
• 摩尔折射率: 99.3738 cm^3
• 极化性: 40.181385 Å^3
• 极化表面积: 124.44 Å^2
• 可自由旋转的化学键: 9
• 里宾斯基五规则: true

分子性质

理化性质

• 溶解度: Chloroform; DMSO; Ethanol; Methanol
• 外观: Off-White Solid
• 熔点: 115-117°C

安全信息

• 保存条件: Hygroscopic, -20°C Freezer, Under Inert Atmosphere

详细说明

Toronto Research Chemicals - B675702

Labelled Bortezomib, whcih the first proteasome inhibitor to be approved b the US FDA for multiple myeloma, a blood cancer. A reversible inhibitor of the 26S proteasome-a barrel-shaped multiprotein particle found in the nucleus and cytosol of all eukaryo

参考文献

• Nawrocki, S.T., et al: Cancer Research, 65, 11510 (2005)